Sacituzumab Govitecan API is a targeted antibody-drug conjugate (ADC) used in oncology. It combines a humanized monoclonal antibody directed against TROP-2 with the cytotoxic topoisomerase-I inhibitor SN-38 through a hydrolysable CL2A linker. This design enables targeted delivery of the cytotoxic payload to TROP-2-expressing cancer cells.
Sacituzumab govitecan is also identified as sacituzumab govitecan-hziy, hRS7-SN38, and IMMU-132. FDA GSRS identifies the substance under UNII M9BYU8XDQ6, while PubChem lists CAS 1491917-83-9.
Unlike conventional chemical APIs, sacituzumab govitecan is a complex biological drug substance whose critical quality attributes include antibody identity, conjugation characteristics, drug-to-antibody ratio, linker integrity, SN-38 content, aggregation, purity and biological activity.
Sacituzumab govitecan consists of three principal components: the hRS7 IgG1κ humanized monoclonal antibody, the CL2A hydrolysable linker, and SN-38. The antibody is produced using mammalian cell culture, while the linker and SN-38 components are produced through chemical synthesis. The components are subsequently conjugated to generate the final ADC.
The ADC has an average drug-to-antibody ratio (DAR) of approximately 7–8 SN-38 molecules per antibody and an approximate molecular weight of 160 kDa. The exact molecular population is inherently heterogeneous because the number and distribution of conjugated SN-38 molecules can vary around the average DAR.
PubChem provides a representative molecular formula of C76H104N12O24S and a calculated molecular weight of 1601.8 g/mol for the small-molecule structural representation recorded in its database. However, this value should not be used as the molecular weight of the intact therapeutic antibody-drug conjugate for pharmaceutical specifications; the regulatory characterization of the ADC is approximately 160 kDa.
Sacituzumab govitecan is an oncology biologic used for the treatment of specific advanced or metastatic cancers.
The current U.S. prescribing information includes use in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Current labeling also includes first-line use in specified patients whose tumors express PD-L1 and treatment of patients who have received previous systemic therapies.
The medicine is administered by intravenous infusion. The current U.S. recommended dose is 10 mg/kg on Days 1 and 8 of a 21-day treatment cycle, continued until disease progression or unacceptable toxicity.
Sacituzumab govitecan targets TROP-2, a cell-surface protein expressed on many epithelial cancers.
After binding to TROP-2, the ADC is internalized by the cancer cell. The hydrolysable CL2A linker facilitates release of the SN-38 payload. SN-38 inhibits topoisomerase I, preventing the re-ligation of topoisomerase-I-associated DNA single-strand breaks. The resulting DNA damage can lead to apoptosis and cancer-cell death.
The linker can also permit extracellular release of SN-38, contributing to a bystander effect against nearby tumor cells. EMA describes both intracellular and extracellular release of SN-38 from the ADC.
Sacituzumab govitecan requires a specialized biologics and ADC quality-control strategy rather than conventional small-molecule API testing.
Important quality attributes include:
EMA's assessment describes batch analysis of the CL2A-SN38 intermediate and confirms that batch-to-batch consistency and improvement in purity were evaluated during development.
Sacituzumab govitecan manufacturing involves multiple controlled stages because it is an ADC rather than a conventional chemically synthesized API.
The hRS7 IgG1κ antibody is produced using mammalian cells, while SN-38 and CL2A are produced through chemical synthesis. These components are subsequently combined through controlled conjugation involving thioether bonds to generate the ADC.
Manufacturing controls must maintain antibody quality, linker integrity, SN-38 loading and the desired average DAR. Purification processes are used to remove unconjugated components, aggregates, process-related impurities and other product-related species.
Sacituzumab govitecan is a complex recombinant antibody-drug conjugate rather than a conventional low-molecular-weight chemical.
Key characteristics include:
The finished pharmaceutical product is supplied as a sterile, preservative-free, off-white to yellowish lyophilized powder in a single-dose vial. The current U.S. label specifies a 180 mg vial.
Unreconstituted vials should be stored at 2°C to 8°C in the original carton and protected from light. The product should not be frozen. Following reconstitution and dilution, additional time- and temperature-controlled handling requirements apply.
A qualified Sacituzumab Govitecan biological/ADC manufacturer can provide applicable documentation, including:
Sacituzumab govitecan requires specialized ADC manufacturing and analytical capabilities because the final biological substance combines a monoclonal antibody with a chemically synthesized linker and cytotoxic payload.
A qualified manufacturing partner should therefore have appropriate capabilities for recombinant antibody production, chemical payload/linker manufacturing, controlled conjugation, purification, DAR characterization, aggregate control, biological activity testing and cold-chain handling.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| pH (1% Solution) | 6.5 |